| Autor: |
Soriano PA; Liver Tumor Program, City of Hope, 1500 E. Duarte Road, Duarte, CA 91010, USA., Liu N, Castillo E, Foster B, Artinyan A, Kim J, Huang W, Wagman LD |
| Jazyk: |
angličtina |
| Zdroj: |
International journal of hepatology [Int J Hepatol] 2011; Vol. 2011, pp. 490463. Date of Electronic Publication: 2011 Nov 22. |
| DOI: |
10.4061/2011/490463 |
| Abstrakt: |
Introduction. We examined the murine hepatectomy model of liver regeneration (LR) in the setting of neoadjuvant chemotherapy. Methods. C57BL/6 mice were randomized to receive neoadjuvant intraperitoneal (IP) injections of a control, oxaliplatin (15 mg/kg), or irinotecan (100 mg/Kg or 250 mg/Kg) solution. Hepatectomy (70%) was performed 14 days after the final IP treatment. Animals were sacrificed at postoperative day (D) 0, 1, 2, 3, and 7. Liver remnants and serum were collected for analysis. T-tests for independent samples were used for statistical comparisons. Results. For oxaliplatin, percent LR did not differ at D1 or D2 but was significantly less at D3 (89.0% versus 70.0%, P = 0.048) with no difference on D7 (P = 0.21). Irinotecan-treated mice at both dose levels (100 mg/Kg and 250 mg/Kg) showed no significant differences in LR. BrdU incorporation was significantly decreased in oxaliplatin-treated animals (D1,2,3). Conclusions. Neoadjuvant oxaliplatin but not irinotecan impairs early LR in a posthepatectomy murine model which correlates with decreased DNA synthesis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
